Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall.

Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to ...

Vertex Pharmaceuticals Inc. said it's stopping work on two potential drugs for a genetic lung disorder, but is now predicting a better-than-expected 2024 product revenue. The Boston drug developer ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.

If you have non-public information about Vertex Pharmaceuticals Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange ...

Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments.

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors.